PARP Inhibitors in the Management of Ovarian Cancer

Publication Date: September 23, 2022

Key Points

Key Points

  • These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
  • The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.

Treatment

...eatment...

Repeating P...

...ndation 1.0Repeating PARPi therapy in...


...Diagnosed Ovarian Cancer...

Recommendation 2.0PARPi are NOT recom...

...d Update – Recommendation 2.1Patients with newly...

...on 2.2The addition of olaparib to b...

...mmendation 2.3Inclusion of the PARPi, veliparib,...


...varian Cancer - Second-line or Greater Maint...

...ate – Recommendation 3.0...

...otherapy maintenance (second-line or more) may...

...eatment with niraparib for patients...

...Recommendation 3.1/3.2PARPi monotherapy...

...apid Update – Recommendation 3.3PARPi monothera...


PARPi in Combina...

...ommendation 4.0PARPi are NOT recomme...


...agement of Adverse Events...

Recommendation 5.0 Anemia...

a. Patients requiring a blood transfusion...

...ients with progressive anemia may be off...

...commendation 5.1 Neutro...

...ctor is NOT indicated for use in patients r...

...tropenia (grade 4 lasting at least 5–7 days or...

...mmendation 5.2 Plate...

...Thrombocytopenia is most common with nirapar...

...ontinue PARPi for persistent thrombocytope...

...ommendation 5.3 Persistent cytopenia:Evalu...

...ndation 5.4 Nausea:...

...ients will have tachyphylaxis of nausea...

...nausea requiring daily anti-emetic i...


.... PARP Inhibitors in the Management o...


Figure 1. PARPi Use Opportunities in...